Centessa Pharmaceuticals (CNTA) Stock Forecast, Price Target & Predictions
CNTA Stock Forecast
Centessa Pharmaceuticals stock forecast is as follows: an average price target of $23.25 (represents a 35.49% upside from CNTA’s last price of $17.16) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
CNTA Price Target
The average price target for Centessa Pharmaceuticals (CNTA) is $23.25 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $19.00. This represents a potential 35.49% upside from CNTA's last price of $17.16.
CNTA Analyst Ratings
According to 8 Wall Street analysts, Centessa Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CNTA stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 2 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Centessa Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | Debjit Chattopadhyay | Guggenheim | $28.00 | $17.10 | 63.74% | 63.17% |
| Sep 19, 2024 | Jeffrey Hung | Morgan Stanley | $26.00 | $15.85 | 64.04% | 51.52% |
| Sep 11, 2024 | Kelly Shi | Jefferies | $19.00 | $14.99 | 26.75% | 10.72% |
| Sep 10, 2024 | Kostas Biliouris | BMO Capital | $20.00 | $16.02 | 24.84% | 16.55% |
| Aug 14, 2024 | Kostas Biliouris | BMO Capital | $15.00 | $12.60 | 19.05% | -12.59% |
The latest Centessa Pharmaceuticals stock forecast, released on Nov 15, 2024 by Debjit Chattopadhyay from Guggenheim, set a price target of $28.00, which represents a 63.74% increase from the stock price at the time of the forecast ($17.10), and a 63.17% increase from CNTA last price ($17.16).
Centessa Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 5 |
| Avg Price Target | - | $27.00 | $21.60 |
| Last Closing Price | $17.16 | $17.16 | $17.16 |
| Upside/Downside | -100.00% | 57.34% | 25.87% |
In the current month, the average price target of Centessa Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Centessa Pharmaceuticals's last price of $17.16. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 15, 2024 | Guggenheim | Buy | Buy | Hold |
| Sep 19, 2024 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| Sep 18, 2024 | B. Riley | Buy | Initialise | |
| Sep 11, 2024 | Jefferies | Buy | Buy | Hold |
| Sep 11, 2024 | Guggenheim | Buy | Buy | Hold |
| Sep 09, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 14, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jul 18, 2024 | Oppenheimer | Outperform | Initialise | |
| Jun 21, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 12, 2022 | Morgan Stanley | Overweight | Underweight | Downgrade |
| Aug 12, 2022 | Morgan Stanley | Overweight | Downgrade | |
| Aug 11, 2022 | Goldman Sachs | Neutral | Neutral | Hold |
| Jun 17, 2022 | BMO Capital | Outperform | Initialise | |
| Apr 26, 2022 | Zacks Investment Research | Hold | Upgrade |
Centessa Pharmaceuticals's last stock rating was published by Guggenheim on Nov 15, 2024. The company gave CNTA a "Buy" rating, the same as its previous rate.
Centessa Pharmaceuticals Financial Forecast
Centessa Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Centessa Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CNTA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Centessa Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict CNTA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Centessa Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Centessa Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-49.21M | $-49.70M | $-47.37M | $-44.47M | $-48.83M | $-46.07M | $-42.39M |
| High Forecast | $-49.21M | $-49.70M | $-47.37M | $-40.96M | $-37.98M | $-46.07M | $-42.39M |
| Low Forecast | $-49.21M | $-49.70M | $-47.37M | $-49.15M | $-77.04M | $-46.07M | $-42.39M |
| Surprise % | - | - | - | - | - | - | - |
Centessa Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CNTA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Centessa Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Centessa Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CNTA last annual SG&A of $NaN (undefined).
Centessa Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.42 | $-0.43 | $-0.41 | $-0.38 | $-0.42 | $-0.40 | $-0.39 |
| High Forecast | $-0.42 | $-0.43 | $-0.41 | $-0.35 | $-0.33 | $-0.40 | $-0.39 |
| Low Forecast | $-0.42 | $-0.43 | $-0.41 | $-0.42 | $-0.66 | $-0.40 | $-0.39 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Centessa Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CNTA previous annual EPS of $NaN (undefined).
Centessa Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HLVX | HilleVax | $1.90 | $32.00 | 1584.21% | Hold |
| STRO | Sutro Biopharma | $2.09 | $13.00 | 522.01% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| OPT | Opthea | $3.27 | $14.00 | 328.13% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
| GNFT | Genfit | $3.66 | $13.00 | 255.19% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
| DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| CNTA | Centessa Pharmaceuticals | $17.60 | $23.25 | 32.10% | Buy |
| NUVL | Nuvalent | $88.10 | $114.80 | 30.31% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.37 | $69.00 | 24.62% | Buy |
| IRON | Disc Medicine | $65.00 | $77.67 | 19.49% | Buy |
| TARS | Tarsus Pharmaceuticals | $53.26 | $63.00 | 18.29% | Buy |
| TRDA | Entrada Therapeutics | $18.45 | $20.00 | 8.40% | Buy |